The U.S. Food and Drug Administration (FDA) has authorized TEZSPIRE (tezepelumab-ekko) for the add-on maintenance therapy of poorly managed chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and above
Eli Lilly and Company has announced strong Phase 3 data for its investigational oral GLP-1 therapy Orforglipron from ACHIEVE-2 and ACHIEVE-5 trials, which could potentially lay the groundwork for a new treatment standard in type 2 diabetes...
On Monday AbbVie proclaimed that its newest arthritis medication, Rinvoq, outperformed the company’s established best-selling product Humira in a head-to-head clinical study. These findings represent a substantial achievement for AbbVie as it...
AbbVie Inc. has fully acquired Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, which represents a major expansion of AbbVie's neuroscience pipeline.
Dr Reddy's Laboratories Ltd reports that it has obtained an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations manufacturing plant (FTO 11) in Srikakulam, Andhra Pradesh...
Boston Scientific Corporation announced a definitive agreement to acquire Nalu Medical, Inc., a privately held medtech company that develops minimally invasive solutions for chronic pain management.
The multi-specialty chain, Ahmedabad-based Shalby Hospital, decided to go for a big expansion plan establishing a pan India presence.
Merck's Phase 3 HIV trial highlights expertise in antiviral science, authority in clinical research, and advancing effective treatments showing minimal metabolic impact and reaffirming Merck's commitment to evidence-based HIV care
Indegene today unveiled its ambitious expansion of the Consulting Practice, reaffirming its ongoing commitment to enable life sciences organizations to navigate value and risk in large transformation efforts, in a complex, technology-driven world...
Iberia Pharmaceuticals, a leading name in skincare, has launched KeyCi, a science-backed skincare brand designed for modern consumers aged 18–45. KeyCi offers high-performance, dermatologically tested products that are vegan, cruelty-free...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")